Announcements Trials
Browse Landscape

Phase

Phase 2 14Phase 3 6Phase 1 3Phase NA 1Phase 4 1Phase 2/3 1Phase 1/2 1

Status

Recruiting 3Unknown 1Completed 1Active not recruiting 1

Sponsor Class

NETWORK 3OTHER 2INDUSTRY 1

Study Type

Interventional 6

Sponsor

Cancer Type

Gastrointestinal 2Tumor-Agnostic 1Thoracic 1Genitourinary 1Breast 1

Conditions

Breast Neoplasms 139Carcinoma, Non-Small-Cell Lung 109Prostatic Neoplasms 51Lung Neoplasms 31Neoplasm Metastasis 21Stomach Neoplasms 18Parkinson Disease 4, Autosomal Dominant Lewy Body 17Nasopharyngeal Carcinoma 16Neoplasms 15Squamous Cell Carcinoma of Head and Neck 14Esophageal Neoplasms 11Head and Neck Neoplasms 8Esophageal Squamous Cell Carcinoma 8Urinary Bladder Neoplasms 7HER2-positive Breast Cancer 7Ovarian Neoplasms 6Carcinoma 6Adenocarcinoma 6Inflammatory Breast Neoplasms 5Fallopian Tube Neoplasms 5Endometrial Neoplasms 5Carcinoma, Squamous Cell 5Adenocarcinoma of Lung 5Triple Negative Breast Neoplasms 4Recurrence 4Carcinoma, Transitional Cell 4Adenocarcinoma Of Esophagus 4Primary Breast Cancer 3Carcinoma, Ovarian Epithelial 3Adenocarcinoma, Bronchiolo-Alveolar 3

Interventions

Oxaliplatin 10Fluorouracil 7Leucovorin 6Gemcitabine 6Docetaxel 6Capecitabine 6Paclitaxel 5Cisplatin 5zolbetuximab 4Ramucirumab 3Pemetrexed 3Drug Therapy 3Carboplatin 3Albumin-Bound Paclitaxel 3130-nm albumin-bound paclitaxel 3regorafenib 2pembrolizumab 2Vinorelbine 2Surgical Procedures, Operative 2Radiotherapy 2Nivolumab 2Neoadjuvant Therapy 2Cyclophosphamide 2Chemoradiotherapy 2Bevacizumab 2Afatinib 2vandetanib 1trifluridine tipiracil drug combination 1trastuzumab deruxtecan 1tislelizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Phase 3 × Adenocarcinoma × Docetaxel × Clear all
NCT06592924 2026-04-14

TRIPLE-SWITCH

Canadian Cancer Trials Group

Phase 3 Recruiting
830 enrolled
Genitourinary

Adenocarcinoma, Prostatic Neoplasms

NCT06908304 2026-01-12

A Phase III Study With THIO + Cemiplimab vs Chemotherapy as 3rd Line Treatment in Advanced/Metastatic NSCLC

Maia Biotechnology

Phase 3 Recruiting
300 enrolled
Thoracic

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Carcinoma, Large Cell

NCT04879368 2025-07-17

INTEGRATEIIb

Australasian Gastro-Intestinal Trials Group

Phase 3 Active not recruiting
450 enrolled
Tumor-Agnostic

Adenocarcinoma, Carcinoma, Neoplasm Metastasis

NCT02509286 2024-05-08

ESOPEC

University Hospital Schleswig-Holstein

Phase 3 Unknown
438 enrolled
Gastrointestinal

Adenocarcinoma Of Esophagus, Adenocarcinoma, Esophageal Neoplasms

NCT05264896 2023-09-07

Perioperative FLOT vs Adjuvant XELOX for CA Stomach

Chinese University of Hong Kong

Phase 3 Recruiting
110 enrolled
Gastrointestinal

Adenocarcinoma, Stomach Neoplasms

NCT00887536 2022-04-20

A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer

NSABP Foundation Inc

Phase 3 Completed
1,613 enrolled
Breast

Adenocarcinoma, Breast Diseases, Breast Neoplasms, Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡